Compare PIII & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PIII | TPST |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 13.7M |
| IPO Year | 2021 | 2012 |
| Metric | PIII | TPST |
|---|---|---|
| Price | $1.63 | $0.29 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.75 | N/A |
| AVG Volume (30 Days) | 32.6K | ★ 182.0K |
| Earning Date | 11-09-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,459,080,000.00 | $295,000.00 |
| Revenue This Year | $7.84 | N/A |
| Revenue Next Year | $7.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.52 | $0.29 |
| 52 Week High | $16.89 | $4.22 |
| Indicator | PIII | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 21.10 | 20.25 |
| Support Level | N/A | N/A |
| Resistance Level | $3.07 | $0.56 |
| Average True Range (ATR) | 0.39 | 0.05 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 1.41 | 4.46 |
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all. It includes utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of its providers, processing and payment of claims, and the establishment of a provider network for certain health plans.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.